Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Ford Investor Services, Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Fibrocell Science Inc Announces Results Of Phase 2 Study Of azficel-T (LAVIV)


Monday, 15 Apr 2013 08:00am EDT 

Fibrocell Science Inc announced that Phase 2 study to evaluate the safety and efficacy of azficel-T (LAVIV) for the treatment of patients with moderate-to-severe acne scars has been accepted for publication in Dermatologic Surgery, the peer-reviewed journal of the American Society for Dermatologic Surgery. The findings demonstrated that azficel-T treatment was associated with clinically meaningful improvement in acne scar appearance and was judged safe and superior to control treatment. 

Company Quote

3.16
-0.22 -6.51%
4:00pm EDT